Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $28.41, for a total value of $142,050.00. Following the sale, the director now directly owns 32,467 shares in the company, valued at $922,387.47. The transaction was disclosed in a filing with the SEC, which is available at this link.
LNTH stock opened at $28.72 on Monday. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.82 and a current ratio of 4.57. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 30.55, a P/E/G ratio of 2.16 and a beta of 1.49. Lantheus Holdings Inc has a 12-month low of $12.59 and a 12-month high of $29.80. The firm’s 50 day moving average price is $26.08.
Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The firm had revenue of $86.51 million for the quarter, compared to analyst estimates of $86.80 million. On average, equities research analysts forecast that Lantheus Holdings Inc will post 1.11 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on LNTH shares. Zacks Investment Research lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. BidaskClub lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $23.33.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Recommended Story: What are the economic characteristics of a bear market?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.